Does higher apolipoprotein B indicate greater cardiovascular risk even with normal triglycerides?

Apolipoprotein B (ApoB) has emerged as a crucial marker for cardiovascular risk assessment, capturing residual risk that traditional lipid panels frequently overlook.

Stoichiometric proxy and atherogenic burden

Each atherogenic lipoprotein particle—including LDL, IDL, VLDL, and Lp(a)—possesses exactly one molecule of ApoB on its surface. Because of this 1:1 stoichiometry, measuring ApoB directly quantifies the absolute concentration of circulating atherogenic particles. This particle count is pathophysiologically critical because the physical retention and accumulation of these particles within the arterial wall directly drive atherosclerotic plaque progression. Quantifying particle count via ApoB provides a more accurate reflection of this cumulative atherogenic burden than measuring the highly variable cholesterol volume contained within those particles (LDL-C).

Risk with normal triglycerides

Clinical and epidemiological data from large-scale cohorts, such as the UK Biobank and the Copenhagen General Population Study, show that elevated ApoB is associated with a progressive increase in the hazard ratio for atherosclerotic cardiovascular disease (ASCVD) and myocardial infarction, even in individuals with normal triglyceride levels. Furthermore, genetic association studies confirm that when ApoB is elevated discordantly relative to LDL-C and triglycerides, coronary artery disease risk remains high. This indicates that cardiovascular risk is heavily driven by the total number of circulating atherogenic particles, regardless of whether a patient exhibits normal triglyceride or cholesterol mass metrics.

Bottom line

• Apolipoprotein B is a highly accurate, stoichiometric proxy for all atherogenic lipoprotein particles, and its elevation indicates heightened cardiovascular risk even when triglyceride levels are completely normal.